Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial

Inclusion Criteria: * Pathologically confirmed pancreatic ductal adenocarcinoma (metastatic or locally advanced stage) * Refractory or progress to Gemcitabine based 1st line chemotherapy * Older than 19 years old and younger than 75 years old * Life expectancy\> 3 months * ECOG Performance status ≤2 * Only patients with measurable lesions in imaging study * Adequete BM function (WBC ≥ 3,500/µl, absolute neutrophil cell count ≥ 1,500 /µl, platelet count ≥ 100,000/µl) * Adequete liver function (total bilirubin \< 1.5 X the upper limits of normal (ULN), AST and ALT \<3 X UNL, and alkaline phosphatases \< 3 X ULN or \< 5 x ULN in case of liver involvement) * Adequete renal function (serum creatinine \< 1.5 mg/dl) * Adequete cardiopulmonary function Exclusion Criteria: * Pathologically confirmed another type of pancreatic cancer (except ductal adenocarcinoma) * Metastatic adenocarcinoma of originating at other organs * Evidence with CNS metastasis * Active infection * Uncontrolled serious medical or psychiatric illness which can induce toxicity ro complication of treatment, such as inability to swallow, lacking physical integrity of the gastrointestinal tract, malabsorption syndrome, or active ulceration at upper gastrointestinal tract. * Coexisting of other malignancies within 5 years, except squamous cell carcinoma and basal cell carcinoma of the skin * Participation in any other investigational drug study within 1 month * No signed informed consent